There are no uniform protocols in the United States for safe, environmentally acceptable disposal of controlled substances by patients. In addition, there are conflicting protocols used by various institutions for the disposal of narcotic medications. Although the US Drug Enforcement Administration oversees the prescribing, acquisition, and distribution of controlled substances and works to prevent the illegal diversion of these products, it stops short of recommending specific mechanisms for consumers to dispose of unused medications. The lack of specific regulations in this area increases the risk of illegal diversion of prescription medications and other controlled substances. The authors review and examine the dilemma posed by an ill-defined set of guidelines for disposal of controlled substances by patients and institutions not registered with the US Drug Enforcement Administration. The authors encourage public officials to update and reform ambiguous policies regarding opioid disposal by consumers and allied healthcare workers.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers.
Psychopharmacol Bull
January 2025
Sychev, corresponding member of the Academy of Sciences of Russia, MD, PhD, MD, professor, rector, head of clinical pharmacology and therapy department, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russian Federation.
Introduction: Alcoholic hallucinosis (AH) is one of the severe complications of chronic alcoholism, characterized by psychotic symptoms such as auditory hallucinations and delusions. Haloperidol is widely used to treat AH; however, its therapy is often complicated by side effects. A personalized approach using pharmacogenetic testing (particularly the CYP2D6 polymorphism) allows individualization of haloperidol dosage, improving both safety and efficacy of therapy.
View Article and Find Full Text PDFPsychedelic Regulation Beyond the Controlled Substances Act: A Three-Dimensional Framework for Characterizing Policy Options.
Am J Psychiatry
January 2025
Department of Psychology, Suffolk University, Boston, Mass. (Mian); Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco (Mian, Dinh, Mitchell, Anderson); Kaiser Permanente Northern California, Division of Research, Oakland, Calif. (Mian); Department of Psychology, Suffolk University, Boston (Mian); Department of Neurology, University of California San Francisco, San Francisco (Coker, Mitchell); Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, Calif. (Coker); Department of Veterans Affairs, Research Service, San Francisco VA Medical Center, San Francisco (Mitchell); UC Berkeley Center for the Science of Psychedelics, Berkeley, Calif. (Mitchell, Anderson).
Primum Non Nocere: The Onus to Characterize the Potential Harms of Psychedelic Treatment.
Am J Psychiatry
January 2025
Department of Psychiatry, Center for the Neuroscience of Psychedelics, Massachusetts General Hospital, Boston (Ghaznavi, King, Rosenbaum); Department of Cardiology, Massachusetts General Hospital, Boston (Ruskin); Department of Psychiatry and Neurology, Chemical Neurobiology Laboratory, Center for the Neuroscience of Psychedelics, Massachusetts General Hospital, Boston (Haggerty); Havard Medical School, Boston (Ghaznavi, Ruskin, Haggerty, King, Rosenbaum).
The last few years have seen exponential growth in interest, investment, advocacy, and research into psychedelics as therapeutics. This reflects an optimism about the potential promise of psychedelics as therapeutics. As with all therapeutic interventions, research is needed not only into their benefits but also potential risks.
View Article and Find Full Text PDFTreatment Effects in Pharmacological Clinical Randomized Controlled Trials are Mainly Due to Placebo.
J Clin Epidemiol
December 2024
Change Health Science Institute, Basel, Switzerland; Next Society Institute, Kazimieras Simonavicius University, Vilnius, Lithuania.
Objectives: The placebo response in clinical trials has four components: regression to the mean (RTM), measurement artefacts, natural tendency (NT) of the disease, and the genuine placebo effect. Our objective is to determine what contributes to the size of the placebo-effect in clinical trials by meta-regressions of randomized placebo-controlled clinical trials.
Study Design And Setting: We identified five diseases where data on the rates of NT were available to search for a sample of n=150 (5x30) RCTs.
The role of biodegradable plastics in lignite anaerobic digestion: Changes of organics transformation and metabolic pathway.
Bioresour Technol
December 2024
School of Energy Science and Engineering, Henan Polytechnic University, Jiaozuo 454000, China. Electronic address:
Biodegradable plastics (BPs) and lignite, both rich in organic matter, present significant challenges for efficient conversion into clean energy. This study examined the anaerobic co-digestion of BPs and lignite under controlled laboratory conditions. The results demonstrated that the co-digestion of polylactic acid (PLA) and lignite (at a 1:2 mass ratio, with 5 g PLA and 10 g lignite as the model system) rapidly acclimated to the anaerobic environment, enhancing cumulative biogas production by 57 % compared to the mono-digestion of lignite alone.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!